Arcus Biosciences Reports First Quarter 2022 Financial Results and Provides a Pipeline Update, Including from the Third Interim Analysis for the ARC-7 Study

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/12/2026

1. ADBE
2. SPCX
3. USO
4. SPY
5. RH
6. NVDA
7. RKLB
8. CRM
9. MSFT
10. MRVL

Go back to Arcus Biosciences Reports First Quarter 2022 Financial Results and Provides a Pipeline Update, Including from the Third Interim Analysis for the ARC-7 Study

Arcus Biosciences (RCUS) Posts Wider-than-Expected Q1 Loss

May 9, 2022 4:52 PM EDT

Arcus Biosciences (NYSE: RCUS) reported Q1 EPS of ($0.96), $0.65 worse than the analyst estimate of ($0.31). Revenue for the quarter came in at $18 million versus the consensus estimate of $79.42 million.

Cash, cash equivalents and investments were $1,342.4 million as of March 31, 2022, compared to $681.3 million as of... More